These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. Ho CL, Lu CS, Chen JH, Chen YG, Huang TC, Wu YY. Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479 [Abstract] [Full Text] [Related]
4. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Seo S, Hong JY, Yoon S, Yoo C, Park JH, Lee JB, Park CS, Huh J, Lee Y, Kim KW, Ryu JS, Kim SJ, Kim WS, Yoon DH, Suh C. Oncotarget; 2016 Nov 22; 7(47):76934-76943. PubMed ID: 27764777 [Abstract] [Full Text] [Related]
5. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma. Zhao F, Qin Y, Yang J, Liu P, He X, Zhou L, Zhou S, Gui L, Zhang H, Wang X, Jiang S, Zhong Q, Zhou Y, Shi Y. Asia Pac J Clin Oncol; 2020 Dec 22; 16(6):385-391. PubMed ID: 32779387 [Abstract] [Full Text] [Related]
6. Prognostic value of absolute lymphocyte/monocyte ratio, red cell distribution width and neutrophil/ lymphocyte ratio in diffuse large B-cell lymphoma patients. Hasan KM, Elmeshhedany AY. Cell Mol Biol (Noisy-le-grand); 2021 Nov 25; 67(3):61-68. PubMed ID: 34933732 [Abstract] [Full Text] [Related]
8. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients. Coutinho R, Lobato J, Esteves S, Cabeçadas J, Gomes da Silva M. Ann Hematol; 2019 Aug 25; 98(8):1937-1946. PubMed ID: 30949752 [Abstract] [Full Text] [Related]
11. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. Procházka V, Pytlík R, Janíková A, Belada D, Sálek D, Papajík T, Campr V, Fürst T, Furstova J, Trněný M. PLoS One; 2014 Aug 25; 9(7):e102594. PubMed ID: 25058337 [Abstract] [Full Text] [Related]
12. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center. Huang H, Fan L, Fu D, Lin Q, Shen J. Ann Palliat Med; 2020 Jul 25; 9(4):1442-1452. PubMed ID: 32648457 [Abstract] [Full Text] [Related]
16. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study. Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N. J Egypt Natl Canc Inst; 2011 Mar 25; 23(1):17-24. PubMed ID: 22099932 [Abstract] [Full Text] [Related]
20. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Walewski J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, Szpila T, Butrym A, Giza A, Zaucha JM, Kalinka-Warzocha E, Wieczorkiewicz A, Zimowska-Curyło D, Knopińska-Posłuszny W, Tyczyńska A, Romejko-Jarosińska J, Dąbrowska-Iwanicka A, Gruszecka B, Jamrozek-Jedlińska M, Borawska A, Hołda W, Porowska A, Romanowicz A, Hellmann A, Stella-Hołowiecka B, Deptała A, Jurczak W. Br J Haematol; 2020 Mar 25; 188(6):898-906. PubMed ID: 31792945 [Abstract] [Full Text] [Related] Page: [Next] [New Search]